

Supplementary material for:

Defective expression of apoptosis-related molecules in multiple sclerosis patients is normalized early after autologous hematopoietic stem cell transplantation

de Oliveira GV et al., 2016

Table S1. Gene expression levels of apoptotic-genes of patients at pre-transplant period (BEAM or Cyclophosmide conditioning regimens) and controls.

Group	N Obs	Variable	N	Mean	Standard Deviation	Minimum	Q1	Median	Q3	Maximum
BEAM	7	A1	5	292.03	343.65	0.14	14.95	173.59	462.31	809.14
		Bcl_2	5	1.47	2.32	0.0002	0.12	0.81	0.86	5.56
		Bcl_w	5	0.72	0.44	0.38	0.47	0.54	0.74	1.47
		Bcl_xL	5	45.59	15.10	24.91	37.20	47.52	54.56	63.77
		Mcl_1	5	5495.59	4753.47	366.65	520.19	7012.92	9514.69	10063.51
		c_Flip	5	64.45	109.54	0.003	12.06	21.01	29.80	259.40
		clAP_1	5	30.90	31.61	7.39	7.56	14.73	44.35	80.49
		clAP_2	5	227.91	255.17	0.17	29.22	232.74	238.47	638.97
		Bad	5	0.04	0.06	0	0	0	0.05	0.14
		Bak	5	7.10	6.04	0	4.39	5.41	9.73	15.97
		Bax	5	0.001	0.001	0	0	0	0	0.003
		Bid	5	698.38	641.12	27.26	110.97	810.54	972.39	1570.76
		Bik	5	2.84	5.03	0.03	0.51	0.75	1.12	11.81
		BimEL	5	29.27	23.61	1.01	12.98	28.49	43.68	60.21
		Bok	5	209.89	428.63	9.18	15.36	22.96	25.43	976.56
		Noxa	5	19.34	36.14	0.14	0.72	5.87	6.18	83.80
		Fas_	5	48.35	33.45	0.14	33.81	53.66	65.66	88.49
FasL	5	6.92	6.63	0.04	0.81	7.68	10.23	15.87		
CONTROL	18	A1	18	111.12	100.19	37.85	52.26	79.97	134.50	458.44
		Bcl_2	18	72.70	99.39	0.16	0.80	24.89	146.45	354.42
		Bcl_w	18	2.97	2.39	0.60	1.01	2.03	4.61	8.18
		Bcl_xL	18	287.66	177.35	25.54	161.87	232.31	438.53	653.43

		Mcl_1	18	8194.19	4344.49	2348.79	5002.59	7537.15	10722.55	18245.09
		c_Flip	18	116.26	85.82	16.52	47.18	96.84	165.43	319.93
		ciAP_1	18	75.26	73.37	4.23	22.93	54.13	94.15	292.45
		ciAP_2	18	150.15	107.17	14.14	78.09	125.44	195.37	470.35
		Bad	18	2.89	3.51	0.05	0.15	1.42	4.71	11.22
		Bak	18	166.75	149.85	0.01	8.38	139.96	276.07	429.02
		Bax	18	13.09	13.91	0.09	2.59	9.62	16.61	45.13
		Bid	18	26.68	39.99	2.01	6.29	13.49	30.12	178.04
		Bik	18	2.26	1.39	0.01	1.26	1.99	3.37	4.83
		BimEL	18	27.85	15.87	9.01	15.44	23.78	33.80	65.41
		Bok	18	2.02	2.17	0.002	0.38	1.49	2.46	7.79
		Noxa	18	82.41	139.06	0.28	7.38	17.56	77.25	512.53
		Fas_	18	78.85	43.20	16.84	43.99	76.42	99.10	192.53
		FasL	18	22.24	13.93	7.16	12.08	18.37	28.53	59.88
CY	11	A1	9	2375.25	4115.04	53.04	189.08	433.10	900.14	11702.09
		Bcl_2	9	56.08	81.92	0.39	4.07	6.33	59.11	228.85
		Bcl_w	9	1.99	2.35	0	0.0002	1.28	4.47	5.47
		Bcl_xL	9	377.49	623.23	77.63	88.86	93.57	282.24	1984.59
		Mcl_1	9	6307.13	4941.27	23.91	1711.48	6462.41	10204.45	13240.66
		c_Flip	9	118.13	118.23	0.75	13.37	118.99	161.74	338.18
		ciAP_1	9	44.0466	66.01	0.25	2.06	6.09	46.92	180.78
		ciAP_2	9	652.13	1200.84	0.05	177.78	319.03	374.61	3833.25
		Bad	9	1.35	1.76	0	0.001	0.07	2.94	4.37
		Bak	9	135.35	178.27	1.14	7.80	47.19	213.29	528.77
		Bax	9	9.18	13.14	0	0.002	0.01	19.17	35.49
		Bid	9	390.39	738.98	1.74	7.74	58.01	106.16	2122.36
		Bik	9	4.54	2.10	0.77	3.49	4.43	5.76	8.35
BimEL	9	416.32	1058.97	0.20	6.61	100.33	133.09	3235.79		

		Bok	9	3.01	2.11	0.56	1.62	1.98	4.19	6.91
		Noxa	9	23.15	33.46	1.53	3.72	9.63	12.34	89.41
		Fas_	9	277.99	272.63	1.10	73.81	145.77	474.82	749.53
		FasL	9	21.56	26.26	2.14	3.96	6.25	32.98	66.46

BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; IL: inferior limit; SL: superior limit; Obs: observations.

Table S2. A1 gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

A1										
Periods	Group	N Obs	N	Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						IL	SL			
Pre	BEAM	7	5	292.03	343.66	-134.68	718.73	0.14	173.59	809.14
	C	18	18	111.12	100.19	61.29	160.95	37.85	79.97	458.44
	CY	11	9	2375.25	4115.04	-787.85	5538.35	53.04	433.10	11702.09
D+180	BEAM	7	7	104.79	94.82	17.09	192.48	3.01	65.91	253.13
	C	18	0
	CY	11	11	1063.19	1245.28	226.59	1899.78	194.48	540.67	4483.33
D+360	BEAM	7	7	216.07	290.09	-52.22	484.36	8.07	147.22	854.38
	C	18	0
	CY	11	11	928.17	857.81	351.88	1504.45	1.93	750.51	2388.44
D+540	BEAM	7	4	161.11	48.74	83.55	238.67	124.90	143.41	232.74
	C	18	0
	CY	11	9	1027.38	1232.71	79.83	1974.93	1.19	625.59	3942.83
D+720	BEAM	7	6	703.14	945.83	-289.46	1695.72	115.28	374.09	2564.01
	C	18	0
	CY	11	8	1349.65	1457.00	131.57	2567.73	256.26	790.63	4270.52

Pre: pre-transplant; BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S3. BCL2 gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Periods	Group	N Obs	N	Median	Standard Deviation	Bcl-2		Minimum	Median	Maximum
						IC 95%				
						IL	SL			
Pre	BEAM	7	5	1.47	2.32	-1.41	4.35	0.0002	0.82	5.56
	C	18	18	72.70	99.39	23.27	122.13	0.16	24.89	354.42
	CY	11	9	56.09	81.92	-6.88	119.05	0.39	6.33	228.85
D+180	BEAM	7	7	2.05	3.23	-0.93	5.038	0	0.31	7.86
	C	18	0
	CY	11	11	16.52	20.38	2.83	30.21	0.18	10.22	63.05
D+360	BEAM	7	7	1.46	2.22	-0.59	3.51	0	0.53	6.02
	C	18	0
	CY	11	11	36.73	50.79	2.60	70.85	0.50	10.92	140.24
D+540	BEAM	7	4	0.85	1.12	-0.93	2.63	0.08	0.40	2.51
	C	18	0
	CY	11	9	25.70	28.03	4.15	47.24	1.49	8.66	66.53
D+720	BEAM	7	6	77.07	166.48	-97.64	251.78	0.80	12.35	416.59
	C	18	0
	CY	11	8	30.56	36.92	-0.30	61.43	3.47	22.39	117.67

Pre: pre-transplant; BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S4. BCL-W gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Periods	Group	N Obs	N	Median	Standard Deviation	Bcl-w		Minimum	Median	Maximum
						IC 95%				
						IL	SL			
Pre	BEAM	7	5	0.72	0.44	0.18	1.27	0.38	0.54	1.47
	C	18	18	2.97	2.39	1.78	4.17	0.60	2.03	8.18
	CY	11	9	1.99	2.35	0.19	3.80	0	1.28	5.47
D+180	BEAM	7	7	1.57	3.09	-1.29	4.42	0	0.18	8.49
	C	18	0
	CY	11	11	3.75	4.23	0.91	6.59	0.09	1.83	10.31
D+360	BEAM	7	7	10.39	16.73	-5.08	25.86	0.09	0.57	39.99
	C	18	0
	CY	11	11	8.83	12.13	0.69	16.98	0	2.03	37.27
D+540	BEAM	7	4	0.54	0.82	-0.76	1.84	0	0.20	1.75
	C	18	0
	CY	11	9	3.29	2.35	1.49	5.10	0.002	2.86	6.57
D+720	BEAM	7	6	3.60	4.56	-1.18	8.39	0	1.59	11.79
	C	18	0
	CY	11	8	3.29	1.72	1.86	4.73	1.32	3.23	6.77

Pre: pre-transplant; BEAM: BCNU, Etoposide, Aracytin and Melphalan; CY: Cyclophosphamide; C: Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S5. BCL-XL gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Bcl-xL										
Periods	Group	N Obs	N	Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						IL	SL			
Pre	BEAM	7	5	45.59	15.10	26.84	64.35	24.91	47.52	63.77
	C	18	18	287.66	177.35	199.47	375.86	25.54	232.31	653.43
	CY	11	9	377.49	623.23	-101.57	856.55	77.63	93.57	1984.59
D+180	BEAM	7	7	122.03	170.84	-35.97	280.04	5.17	73.24	504.59
	C	18	0
	CY	11	11	175.93	100.15	108.65	243.21	76.89	148.06	427.76
D+360	BEAM	7	7	197.88	359.53	-134.63	530.39	10.68	66.68	1008.16
	C	18	0
	CY	11	11	1860.66	5406.55	-1771.51	5492.82	87.31	164.55	18154.85
D+540	BEAM	7	4	45.74	12.01	26.62	64.85	34.68	44.08	60.11
	C	18	0
	CY	11	9	99.54	77.03	40.33	158.75	28.39	81.75	247.49
D+720	BEAM	7	6	898.69	1587.90	-767.71	2565.09	80.35	295.26	4117.01
	C	18	0
	CY	11	8	119.14	57.86	70.78	167.51	35.12	110.21	190.81

Pre: pre-transplant; BEAM: BCNU, Etoposide, Aracytin and Melphalan; CY: Cyclophosphamide; C: Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S6. MCL-1 gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Mcl_1										
Periods	Group	N Obs	N	Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						IL	SL			
Pre	BEAM	7	5	5495.59	4753.47	-406.62	11397.80	366.65	7012.92	10063.51
	C	18	18	8194.19	4344.49	6033.73	10354.66	2348.79	7537.15	18245.09
	CY	11	9	6307.13	4941.27	2508.94	10105.32	23.91	6462.42	13240.66
D+180	BEAM	7	7	5158.56	3016.58	2368.68	7948.43	425.35	5165.38	10092.59
	C	18	0
	CY	11	11	13304.11	8970.25	7277.81	19330.40	4220.11	10833.83	34616.83
D+360	BEAM	7	7	18566.43	28898.64	-8160.36	45293.22	19.32	9021.90	83464.62
	C	18	0
	CY	11	11	8094.04	4621.29	4989.40	11198.67	3.78	9046.91	14022.71
D+540	BEAM	7	4	7555.39	1876.97	4568.71	10542.08	5770.89	7590.34	9270.01
	C	18	0
	CY	11	9	10089.98	8994.58	3176.13	17003.82	0.99	8297.94	31180.72
D+720	BEAM	7	6	9998.22	9849.23	-337.9137	20334.36	3276.17	5803.76	28422.63
	C	18	0
	CY	11	8	7034.14	6841.52	1314.4912	12753.79	1737.89	4845.18	23031.89

Pre: pre-transplant; BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S7. C-FLIP gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Periods	Group	N Obs	N	Median	Standard Deviation	c_Flip		Minimum	Median	Maximum
						IC 95%				
						IL	SL			
Pre	BEAM	7	5	64.45	109.54	-71.55	200.46	0.003	21.00	259.40
	C	18	18	116.26	85.82	73.57	158.94	16.52	96.84	319.93
	CY	11	9	118.13	118.23	27.24	209.01	0.75	118.99	338.18
D+180	BEAM	7	7	26.82	24.96	3.74	49.91	0.03	16.79	66.18
	C	18	0
	CY	11	11	190.61	119.36	110.42	270.79	73.16	167.68	445.62
D+360	BEAM	7	7	171.99	218.73	-30.31	374.28	10.85	95.65	644.81
	C	18	0
	CY	11	11	166.76	131.31	78.55	254.97	5.32	118.88	427.21
D+540	BEAM	7	4	103.75	30.26	55.59	151.91	77.09	96.68	144.56
	C	18	0
	CY	11	9	459.84	487.58	85.05	834.63	0.14	196.99	1261.78
D+720	BEAM	7	6	80.81	116.57	-41.53	203.15	0.0001	22.26	287.77
	C	18	0
	CY	11	8	676.92	337.28	394.94	958.89	345.03	595.16	1360.43

Pre: pre-transplant; BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S8. cIAP-1 gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

cIAP-1										
Periods	Group	N Obs	N	Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						IL	SL			
Pre	BEAM	7	5	30.90	31.61	-8.35	70.16	7.39	14.73	80.49
	C	18	18	75.26	73.38	38.77	111.75	4.23	54.13	292.45
	CY	11	9	44.05	66.01	-6.69	94.78	0.25	6.09	180.78
D+180	BEAM	7	7	12.68	13.52	0.18	25.19	3.07	7.97	41.12
	C	18	0
	CY	11	11	87.84	52.12	52.83	122.85	29.55	62.03	181.77
D+360	BEAM	7	7	21.17	30.23	-6.79	49.12	1.69	10.15	88.24
	C	18	0
	CY	11	11	162.15	272.96	-21.23	345.53	0.62	78.44	959.72
D+540	BEAM	7	4	37.09	19.95	5.35	68.83	19.49	31.55	65.76
	C	18	0
	CY	11	9	294.51	593.43	-161.64	750.66	5.28	46.34	1854.92
D+720	BEAM	7	6	105.59	118.84	-19.12	230.32	6.49	62.89	334.41
	C	18	0
	CY	11	8	250.49	228.41	59.54	441.45	16.41	175.34	628.

Pre: pre-transplant; BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S9. cIAP-2 gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

cIAP-2										
Periods	Group	N Obs	N	Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						IL	SL			
Pre	BEAM	7	5	227.91	255.17	-88.92	544.75	0.17	232.74	638.97
	C	18	18	150.15	107.17	96.85	203.44	14.14	125.44	470.35
	CY	11	9	652.13	1200.84	-270.92	1575.18	0.05	319.03	3833.25
D+180	BEAM	7	7	467.31	940.02	-402.07	1336.68	18.79	60.21	2577.51
	C	18	0
	CY	11	11	1199.28	1546.15	160.56	2237.99	147.04	429.83	4422.49
D+360	BEAM	7	7	1673.13	3343.66	-1419.24	4765.50	28.62	361.69	9214.73
	C	18	0
	CY	11	11	377.01	333.49	152.98	601.05	0.01	277.72	1004.29
D+540	BEAM	7	4	1328.03	1358.61	-833.81	3489.88	93.23	1345.91	2527.08
	C	18	0
	CY	11	9	1049.93	1335.72	23.21	2076.66	25.17	259.29	3400.63
D+720	BEAM	7	6	503.74	366.31	119.32	888.16	2.21	602.18	985.31
	C	18	0
	CY	11	8	1011.57	766.47	370.79	1652.36	88.07	803.22	2469.74

Pre: pre-transplant; BEAM: BCNU, Etoposide, Aracytin and Melphalan; CY: Cyclophosphamide; C: Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S10. BAD gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Descriptivas : Bad										
Periods	Group	N Obs	N	Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						IL	SL			
Pre	BEAM	7	5	0.04	0.06	-0.04	0.11	0	0	0.14
	C	18	18	2.89	3.51	1.15	4.64	0.05	1.42	11.22
	CY	11	9	1.35	1.76	-0.0001	2.70	0	0.07	4.37
D+180	BEAM	7	7	0.01	0.017	-0.01	0.02	0	0	0.04
	C	18	0
	CY	11	11	1.75	3.06	-0.30	3.80	0	0.66	9.69
D+360	BEAM	7	7	0.07	0.17	-0.09	0.23	0	0.0001	0.46
	C	18	0
	CY	11	11	1.28	1.71	0.14	2.43	0	0.75	4.71
D+540	BEAM	7	4	0.0001	0.0001	-0.0002	0.0003	0	0	0.0003
	C	18	0
	CY	11	9	1.04	1.15	0.16	1.92	0	0.55	2.67
D+720	BEAM	7	6	0.01	0.01	-0.001	0.02	0	0.01	0.02
	C	18	0
	CY	11	8	1.67	1.83	0.14	3.20	0.30	0.89	5.82

Pre: pre-transplant; BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S11. BAK gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Bak										
Periods	Group	N Obs	N	Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						IL	SL			
Pre	BEAM	7	5	7.10	6.05	-0.41	14.60	0	5.41	15.97
	C	18	18	166.75	149.85	92.24	241.27	0.01	139.96	429.02
	CY	11	9	135.35	178.27	-1.68	272.38	1.14	47.19	528.77
D+180	BEAM	7	7	13.99	15.39	-0.24	28.22	0.67	11.21	46.55
	C	18	0
	CY	11	11	177.96	157.76	71.97	283.94	10.52	166.38	459.10
D+360	BEAM	7	7	51.57	88.83	-30.58	133.72	0	12.54	246.52
	C	18	0
	CY	11	11	310.04	425.08	24.46	595.61	12.53	193.21	1498.39
D+540	BEAM	7	4	180.16	339.30	-359.74	720.07	5.42	13.08	689.08
	C	18	0
	CY	11	9	319.19	408.07	5.53	632.86	3.74	155.59	1210.29
D+720	BEAM	7	6	810.27	833.95	-64.91	1685.45	0.02	603.48	2394.04
	C	18	0
	CY	11	8	111.78	57.62	63.61	159.95	27.74	127.25	196.21

Pre: pre-transplant; BEAM: BCNU, Etoposide, Aracytin and Melphalan; CY: Cyclophosphamide; C: Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S12. BAX gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Bax										
Periods	Group	N Obs	N	Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						IL	SL			
Pre	BEAM	7	5	0.001	0.002	-0.001	0.003	0	0	0.003
	C	18	18	13.09	13.91	6.17	20.01	0.08	9.62	45.13
	CY	11	9	9.18	13.14	-0.92	19.28	0	0.01	35.49
D+180	BEAM	7	7	0	0	.	.	0	0	0
	C	18	0
	CY	11	11	10.64	12.14	2.48	18.79	0	8.32	28.98
D+360	BEAM	7	7	0.16	0.42	-0.23	0.55	0	0	1.11
	C	18	0
	CY	11	11	10.06	10.02	3.33	16.78	0	7.51	35.36
D+540	BEAM	7	4	0	0	.	.	0	0	0
	C	18	0
	CY	11	9	14.69	15.55	2.73	26.64	0	5.98	46.95
D+720	BEAM	7	6	1.22	2.99	-1.91	4.35	0	0	7.31
	C	18	0
	CY	11	8	17.78	10.57	8.94	26.61	3.14	21.23	29.37

Pre: pre-transplant; BEAM: BCNU, Etoposide, Aracytin and Melphalan; CY: Cyclophosphamide; C: Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S13. BID gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Periods	Group	N Obs	N	Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						Bid				
						IL	SL			
Pre	BEAM	7	5	698.39	641.12	-97.67	1494.45	27.26	810.54	1570.76
	C	18	18	26.68	39.99	6.79	46.56	2.01	13.49	178.04
	CY	11	9	390.39	738.98	-177.63	958.42	1.74	58.01	2122.36
D+180	BEAM	7	7	447.69	355.88	118.56	776.83	109.54	471.97	1069.05
	C	18	0
	CY	11	11	2546.08	3580.43	140.72	4951.44	43.31	1617.28	12528.53
D+360	BEAM	7	7	6483.03	15568.04	-7915.00	20881.06	14.94	391.85	41752.56
	C	18	0
	CY	11	11	1764.91	3009.93	-257.18	3787.01	33.89	469.74	9892.50
D+540	BEAM	7	4	1772.63	1160.74	-74.37	3619.63	565.54	1696.85	3131.27
	C	18	0
	CY	11	9	454.25	560.59	23.34	885.16	22.99	143.33	1709.36
D+720	BEAM	7	6	1164.05	1141.51	-33.89	2361.99	101.53	873.80	3393.20
	C	18	0
	CY	11	8	189.69	93.86	111.22	268.16	39.41	203.46	311.20

Pre: pre-transplant; BEAM: BCNU, Etoposide, Aracytin and Melphalan; CY: Cyclophosphamide; C: Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S14. BIK gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Periods	Group	N Obs	N	Median	Standard Deviation	Bik		Minimum	Median	Maximum
						IC 95%				
						IL	SL			
Pre	BEAM	7	5	2.85	5.03	-3.39	9.09	0.04	0.75	11.81
	C	18	18	2.26	1.39	1.57	2.95	0.01	1.99	4.83
	CY	11	9	4.54	2.10	2.92	6.16	0.77	4.43	8.35
D+180	BEAM	7	7	4.91	2.89	2.24	7.58	0.51	5.41	8.81
	C	18	0
	CY	11	11	5.85	8.68	0.024	11.68	0.40	3.84	30.77
D+360	BEAM	7	7	3.09	2.76	0.53	5.64	1.16	1.85	7.59
	C	18	0
	CY	11	11	17.78	46.62	-13.54	49.11	0.65	3.21	158.15
D+540	BEAM	7	4	8.26	12.64	-11.86	28.38	1.23	2.31	27.21
	C	18	0
	CY	11	9	6.63	7.50	0.87	12.39	0.41	3.76	24.20
D+720	BEAM	7	6	6.56	5.29	1.01	12.11	1.25	4.39	14.75
	C	18	0
	CY	11	8	1.41	1.27	0.35	2.47	0.02	1.29	3.44

Pre: pre-transplant; BEAM: BCNU, Etoposide, Aracytin and Melphalan; CY: Cyclophosphamide; C: Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S15. BIMEL gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Periods	Group	N Obs	N	Median	Standard Deviation	BimEL		Minimum	Median	Maximum
						IC 95%				
						IL	SL			
Pre	BEAM	7	5	29.27	23.61	-0.04	58.58	1.01	28.49	60.21
	C	18	18	27.85	15.87	19.96	35.75	9.01	23.78	65.41
	CY	11	9	416.32	1058.97	-397.68	1230.31	0.20	100.33	3235.79
D+180	BEAM	7	7	42.72	45.55	0.59	84.85	6.70	28.51	141.39
	C	18	0
	CY	11	11	64.64	41.67	36.65	92.63	27.48	57.95	182.38
D+360	BEAM	7	7	68.63	99.94	-23.79	161.06	3.61	31.57	290.57
	C	18	0
	CY	11	11	79.81	60.03	39.48	120.14	7.19	68.46	204.49
D+540	BEAM	7	4	37.86	23.33	0.74	74.99	13.16	37.65	62.70
	C	18	0
	CY	11	9	196.24	386.67	-100.98	493.46	8.41	44.85	1209.48
D+720	BEAM	7	6	197.19	181.70	6.51	387.87	34.02	172.69	532.75
	C	18	0
	CY	11	8	142.52	132.09	32.09	252.95	16.18	118.77	449.24

Pre: pre-transplant; BEAM: BCNU, Etoposide, Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S16. BOK gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Periods	Group	N Obs	N	Median	Standard Deviation	Bok		Minimum	Median	Maximum
						IC 95%				
						IL	SL			
Pre	BEAM	7	5	209.90	428.63	-322.31	742.11	9.18	22.96	976.5645
	C	18	18	2.02	2.17	0.94	3.10	0.002	1.49	7.7893
	CY	11	9	3.01	2.11	1.38	4.63	0.5584	1.98	6.9101
D+180	BEAM	7	7	326.70	647.92	-272.53	925.93	4.60	13.31	1739.7948
	C	18	0
	CY	11	11	51.09	86.49	-7.01	109.20	0.28	1.78	222.3663
D+360	BEAM	7	7	100.13	161.24	-48.99	249.25	10.79	36.20	460.4204
	C	18	0
	CY	11	11	150.85	324.39	-67.08	368.78	0.002	6.63	963.8325
D+540	BEAM	7	4	53.21	60.65	-43.31	149.72	0.90	42.56	126.8039
	C	18	0
	CY	11	9	10.24	22.80	-7.28	27.76	0.001	2.42	70.5923
D+720	BEAM	7	6	8.31	15.61	-8.08	24.69	0.41	1.67	40.014
	C	18	0
	CY	11	8	29.54	44.24	-7.45	66.53	0.03	2.05	109.9989

Pre: pre-transplant; BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S17. NOXA gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Periods	Group	N Obs	N	Median	Standard Deviation	Noxa		Minimum	Median	Maximum
						IC 95%				
						IL	SL			
Pre	BEAM	7	5	19.34	36.14	-25.53	64.22	0.14	5.87	83.80
	C	18	18	82.41	139.06	13.26	151.57	0.28	17.56	512.53
	CY	11	9	23.15	33.46	-2.57	48.87	1.53	9.63	89.41
D+180	BEAM	7	7	6.49	9.19	-2.01	14.99	0.006	3.92	26.70
	C	18	0
	CY	11	11	50.16	71.37	2.22	98.11	3.35	23.75	238.92
D+360	BEAM	7	7	8.54	5.72	3.25	13.83	1.34	10.32	15.94
	C	18	0
	CY	11	11	18.53	15.25	8.29	28.78	0.91	12.26	48.39
D+540	BEAM	7	4	7.41	3.77	1.41	13.41	3.11	7.82	10.89
	C	18	0
	CY	11	9	26.58	23.84	8.25	44.91	0.03	22.50	56.84
D+720	BEAM	7	6	14.33	21.22	-7.95	36.60	0.01	6.92	56.58
	C	18	0
	CY	11	8	20.27	16.71	6.30	34.24	3.31	15.12	42.70

Pre: pre-transplant; BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S18. FAS gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Periods	Group	N Obs	N	Fas						
				Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						IL	SL			
Pre	BEAM	7	5	48.35	33.45	6.82	89.88	0.14	53.66	88.50
	C	18	18	78.85	43.20	57.36	100.33	16.84	76.42	192.53
	CY	11	9	277.99	272.63	68.44	487.56	1.10	145.77	749.53
D+180	BEAM	7	7	97.28	61.03	40.84	153.72	3.41	109.22	198.59
	C	18	0
	CY	11	11	278.55	223.24	128.58	428.52	40.75	258.70	707.71
D+360	BEAM	7	7	119.86	87.66	38.79	200.94	47.98	91.57	308.57
	C	18	0
	CY	11	11	305.07	307.66	98.38	511.75	0	159.51	934.24
D+540	BEAM	7	4	191.81	48.69	114.33	269.30	157.20	174.71	260.62
	C	18	0
	CY	11	9	203.52	209.32	42.62	364.41	0.037	140.87	604.41
D+720	BEAM	7	6	187.85	142.77	38.01	337.68	0.17	225.95	348.50
	C	18	0
	CY	11	8	143.28	104.25	56.12	230.44	40.38	110.28	357.09

Pre: pre-transplant; BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.

Table S19. FASL gene expression levels of gene in patients at pre- and post- transplantation periods (BEAM or CY conditioning regimens groups) and controls.

Periods	Group	N Obs	N	FasL						
				Median	Standard Deviation	IC 95%		Minimum	Median	Maximum
						IL	SL			
Pre	BEAM	7	5	6.92	6.64	-1.31	15.17	0.04	7.68	15.87
	C	18	18	22.24	13.93	15.31	29.17	7.16	18.38	59.88
	CY	11	9	21.56	26.26	1.38	41.75	2.14	6.26	66.46
D+180	BEAM	7	7	22.54	26.04	-1.54	46.62	0.15	18.26	76.17
	C	18	0
	CY	11	11	43.45	43.15	14.47	72.44	9.65	25.21	125.16
D+360	BEAM	7	7	37.08	46.68	-6.09	80.25	0.84	17.55	120.71
	C	18	0
	CY	11	11	23.96	31.96	2.49	45.43	0	13.19	96.16
D+540	BEAM	7	4	36.84	35.48	-19.62	93.30	4.84	29.56	83.39
	C	18	0
	CY	11	9	34.29	42.31	1.77	66.82	0	12.85	117.78
D+720	BEAM	7	6	43.55	41.60	-0.10	87.21	0	35.83	120.12
	C	18	0
	CY	11	8	22.23	16.19	8.70	35.77	6.58	15.03	51.11

Pre: pre-transplant; BEAM: BCNU. Etoposide. Aracytin and Melphalan; CY: Cyclophosphamide; C; Controls (healthy individuals); IL: inferior limit; SL: superior limit; Obs: observations.